O uso do fumarato de vonoprazana na prevenção do esôfago de Barrett em pacientes com doença do refluxo gastroesofágico: uma revisão sistemática

Gastroesophageal reflux disease (GERD) is a chronic condition that can progress to Barrett's esophagus, a premalignant lesion associated with esophageal adenocarcinoma. Proton pump inhibitors (PPIs) are widely used but show limited long-term efficacy. In this context, vonoprazan, a potassium-competitive acid blocker (P-CAB), has emerged as a promising therapeutic alternative. This study is a qualitative, descriptive, and analytical systematic review that evaluated evidence on the efficacy of vonoprazan in preventing Barrett's esophagus in patients with GERD. Data were collected from PubMed and SciELO using DeCS/MeSH descriptors combined with Boolean operators, including studies published between 2015 and 2025 in Portuguese and English. Twelve studies met the inclusion criteria. The findings showed that vonoprazan achieved higher healing rates, longer symptom control, and lower recurrence of esophagitis compared with PPIs, with a favorable safety profile. It is concluded that vonoprazan is an effective and safe option for preventing the progression of GERD to Barrett's esophagus, although further long-term clinical studies are needed to confirm its therapeutic potential.